oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
LOW DOSE MAGNESIUM SULPHATE REGIME FOR ECLAMPSIA  [PDF]
Bangal V,Kwatra A,Raghav S,Jadhav S
Pravara Medical Review , 2009,
Abstract: Pre- eclampsia is one of the commonest medical complications seen during pregnancy. It contributes significantly to maternal and perinatal morbidity and mortality. Dr.J.A.Pritchard in 1955, introduced magnesium sulphate for control of convulsions in eclampsia and is used worldwide. Considering the low body mass index of indian women, a low dose magnesium sulphate regime has been introduced by some authors. Present study was carried out at tertiary care centre in rural area. Fifty cases of eclampsia were randomly selected to find out the efficacy of low dose magnesium sulphate regime to control eclamptic convulsions. Maternal and perinatal outcome and magnesium toxicity were analyzed. It was observed that 86% cases responded to initial intravenous dose of 4 grams of 20% magnesium sulphate . Eight percent cases, who got recurrence of convulsion, were controlled by additional 2 grams of 20% magnesium sulphate. Six percent cases required shifting to standard Pritchard regime, as they did not respond to low dose magnesium sulphate regime. The average total dose of magnesium sulphate required for control of convulsions was 20 grams ie. 54.4% less than that of standard Pritchard regime. The maternal and perinatal morbidity and mortality in the present study werecomparable to those of standard Pritchard regime. The study did not find a single case of magnesium related toxicity with low dose magnesium sulphate regime. Low dose magnesium sulphate regime was found to be safe and effective in eclampsia.
Body friendly, safe and effective regimen of MgSO4 for eclampsia  [PDF]
Gautam S. Aher, Urmila Gavali
International Journal of Medical Research and Health Sciences , 2013,
Abstract: Pre-eclampsia and eclampsia are major health problems in developing countries. MgSO4 is the standard drug in the control of convulsions in eclampsia. Our study carried out at PDVVPF’s hospital is based on the low dose regimen than Pritchard, which is suitable for Indian women who are of smaller built thanwomen in western world. This prospective study included 50 eclampsia patients receiving low dose MgSO4 therapy. The loading dose of MgSO4 was 9gm. Following this 2.5 gm was given intramuscularly every 6 hourly for 24 hours after administration of the loading dose. Patients were monitored hourly by observing their respiratory rate, knee jerk and urine output. Out of 50, two patients required Pritchard regimen, rest completely recovered from eclampsia. The maternal and perinatal morbidity and mortality were comparable to those of the standard Pritchard regime. The study did not find a single case of magnesium related toxicity with low dose MgSO4 regime. Low dose magnesium sulphate regime was found to be safe and effective in eclampsia
The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia
J Tukur
Annals of African Medicine , 2009,
Abstract: Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. There is now evidence that magnesium sulphate is the most effective anticonvulsant. Method : In this article , a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate. Results : The drug is administered by the Pritchard or Zuspan regimen, although modifications in the two protocols have been reported. Conclusion : A Nigerian national protocol has been developed on its use. There is need for further training of health workers on how to use this important drug.
The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia  [cached]
Tukur Jamilu
Annals of African Medicine , 2009,
Abstract: Background : Pre-eclampsia and eclampsia are important causes of maternal and perinatal morbidity and mortality in the developing countries. There is need to provide the most effective management to pre-eclamptic and eclamptic patients. There is now evidence that magnesium sulphate is the most effective anticonvulsant. Method : In this article , a literature review was made on the contribution of pre-eclampsia and eclampsia to maternal mortality and how it can be curtailed by the use of magnesium sulphate. Results : The drug is administered by the Pritchard or Zuspan regimen, although modifications in the two protocols have been reported. Conclusion : A Nigerian national protocol has been developed on its use. There is need for further training of health workers on how to use this important drug.
ECLAMPSIA
TASNEEM ASHRAF
The Professional Medical Journal , 2004,
Abstract: Objective: To evaluate incidence, morbidity andmortality associated with Eclampsia. Design: Prospective study of 98 cases of eclampsia. Setting: departmentof obstetrics and gynaecology unit II Bolan Medical Collage Complex Quetta. Patients: 98 cases were admittedwith eclampsia during two years and six months period from 1st June 2001 to December 2003. Results: Totalno of admissions were 6952. 98 patients presented with eclampsia making a frequency of 1.40%. Of these 98cases of eclampsia 58 % were primigravidas, mean age of eclamptic patients was 34 years. Gestational age atadmission was less than 35 weeks in 80(78.4%) cases. 54(55%) patients had intrapartum eclampsia.64 (66.7%)patients received diazepam and rest received Magnesium sulphate as anticonvulsant. Caesarean section was donein 10 (11.49%) cases rest delivered vaginally. Fetal loss was seen in 72(82.75%) patients, while 7(7.14%) mothersdied of eclampsia. Conclusion: Maternal and perinatal mortality and morbidity is very high in eclempticpatients. Magnesium sulphate is good anticonvulsant, helpful in reducing maternal morbidity and mortalityconsiderably. Good antenatal practices, maternal education and awareness, provision of better health facilitiesand their utilization will definitely improve maternal and fetal outcome.
ECLAMPSIA
SHAHIDA SHERAZ
The Professional Medical Journal , 2006,
Abstract: Objective: To evaluate incidence, morbidity and mortalityassociated with eclampsia. Design: A prospective study. Place and Duration: The study which was carried out at PAFHospital Rafiqui, Shorkot spanned over a period of 2 years from Jun 2002-Dec 2004. Patients and Methods: Thestudy comprises of 55 eclamptic cases diagnosed out of 3391 consecutive deliveries, carried out in our hospital.Results: The incidence of eclampsia, in this study, was found to be 1.62%. Out of 55 cases 38(69.1%) patients wereprimigravida. Forty three (78.2%) of the patients were between the ages of 21 to 30 years. In 50(90.9%) patientsgestational age was less than 35 weeks. Thirty seven (67.3%) cases had antepartum eclampsia. Forty four (80%)patients received diazepam while the remaining 11(20%) received magnesium sulphate (MgSO4) as anticonvulsant.Commonest mode of delivery was spontaneous vaginal delivery (31 cases, 56.4%) followed by lower caesareansection (21 cases, 38.2%). Fetal loss was seen in 12(20.7%) cases. Two patients died of eclampsia, maternal mortalityrate being 3.6%. Conclusion: Eclampsia is a life threatening complication of pregnancy. However an improvement inantenatal care, upgrading the neonatal facilities and early delivery by cesarean section can improve the perinataloutcome.
RF Controllable Ioffe-Pritchard Trap  [PDF]
G. A. Kouzaev,K. J. Sand
Physics , 2006,
Abstract: An Ioffe-Pritchard trap for cold dressed atoms is studied by analytical and numerical simulations. The effective potential in this trap is formed by the static magnetic and radio-frequency fields, and the minimums are formed around the current bars. The depth of the minimums and the overall topology of the effective potential are controlled electronically. The studied regime of the Ioffe-Pritchard trap is of interest for high-sensitive cold atom interferometers.
INTOXICACIóN POR SULFATO DE MAGNESIO EN PACIENTES CON PREECLAMPSIA Y ECLAMPSIA E INSUFICIENCIA RENAL
Almuna V,Ramón; Sanhueza R,Pablo; Chahuán I,Karina; Arab E,Clemente;
Revista chilena de obstetricia y ginecología , 2004, DOI: 10.4067/S0717-75262004000100009
Abstract: two clinical cases of pregnant women who developed magnesium sulphate intoxication after its use for eclampsia and preeclampsia treatment are reported. the use of magnesium in these patients that also presented renal failure is discussed. a 19 year old patient with eclampsia and acute renal failure, and a 33 year old with chronic hypertension plus preeclampsia and chronic renal failure are presented. both patients were treated with intravenous magnesium sulphate. we describe clinical and laboratory findings during maternal sulphate intoxication. conclusion: treatment with magnesium sulphate for patients with preeclampsia or eclampsia complicated with renal failure is not contraindicated, but magnesium sulphate levels must be strictly controlled
Prevention of Pre-Eclampsia and Eclampsia. A Systematic Review  [PDF]
Sabiha Khanum, Najma Naz, Maria de Lourdes de Souza
Open Journal of Nursing (OJN) , 2018, DOI: 10.4236/ojn.2018.81003
Abstract:
Every pregnant woman needs continuous, timely and supportive care throughout during pregnancy for safe motherhood. The objective of this study was to analyze and evaluate the available medications and techniques for the prevention and treatment of pre-eclampsia and eclampsia. The standard methodology of systematic review without meta-analysis was followed and only RCTs and systematic reviews were included in the review. Three electronic data sources (PubMed/Medline, CINAHL, and Cochrane) were searched for studies, published between 1986 and 2016 on the prevention and control of pre-eclampsia and eclampsia. 47 studies were finally included in the review, of which 18 were systematic reviews and 29 were RCTs. Technologies and techniques used in the included studies for the prevention and control of pre-eclampsia and eclampsia are Magnesium Sulphate, Aspirin, Antioxidant (Vitamin C, E and Lycopene), Calcium supplementation, Chinese Herbal Medicine, physical activities, Nitric Oxide, Marine Food Oils, Low Salt Diet, Garlic, Plasma Volume Expansion, Low-dose Dopamine, Progesterone, Smoking, and Diuretics. Magnesium sulfate appears to be the most effective treatment which reduces the risk of eclampsia by more than 50%. However, its best dose and route are still controversial and need further research. The knowledge and experience of nurses in properly using the protocols and evidence-based interventions are necessary for the wellbeing of pregnant women.
Trends in eclampsia at Korle Bu Teaching Hospatal, Accra Ghana
R Acquah-Arhin, EY Kwawukuwe
Nigerian Journal of Clinical Practice , 2003,
Abstract: Objectives: The aim of the study was to find out the current trend of eclampsia and the incidence in Korle Bu Teaching hospital Method: Case files of all patients who were managed as eclampsia from 1st January 1998 to 31st December 200 were reviewed Result: The incidence of eclampisa during the study period was 15.82 per 1000 deliveries and the fatality rate for eclampsia was 4.78%. About 36.25 of the patients did not receive any form of magnesium sulphate and about 47.5% of the patients arrived at the hospital in taxicabs Conclusion: The results suggested that the incidence of eclampsia had risen from 11.1to 15.82 per 1000 deliveries. It was concluded that magnesium sulphate should be made available in the district hospitals and the polyclinics. Protocol for its use should be circulated and enforced. In addition the ministry of Health could organize a pool of ambulance services for reasonable fees for the public. KEY WORDS: Eclampsia, Magnesium sulphate, maternal deaths. Nigerian Journal of Clinical Practice Vol.6(1) 2003: 1-4
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.